title: Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
abstract: Extravasation and intravasation of tumor cells in solid malignant tumors is controlled by 3 steps: 1) attachment to and interaction of tumor cells with components of the basement membrane and the extracellular matrix, 2) local proteolysis, and 3) tumor cell migration. Evidence has accumulated that different types of tumor-associated proteases, their inhibitors and receptors are involved in tumor invasion and metastasis. Four different classes of proteases are known to be correlated with the malignant phenotype: 1) Matrix metalloproteases; including collagenases, gelatinases and stromelysins. 2) Cysteine proteases; including cathepsins B and L. 3) Aspartyl protease cathepsin D. 4) Serine proteases; including plasmin and tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). A strong independent prognostic value (relapse-free and/or overall survival) has especially been demonstrated for uPA and its inhibitor PAI-1 in patients with cancer of the breast, ovary, stomach, esophagus, colon, lung, and kidney thus predicting the course of the cancer disease. The strong correlation between elevated uPA and/or PAI-1 values in primary cancer tissues and the malignant phenotype of cancer cells has prompted to explore new tumor biology-oriented concepts in order to suppress uPA or uPA receptor (CD87) expression or to abrogate interaction of uPA with CD87. Various very different approaches to interfere with the expression or reactivity of uPA or CD87 at the gene or protein level were successfully tested including antisense oligonucleotides, antibodies, inhibitors and recombinant or synthetic uPA and CD87 analogues.
authors.affiliation: Frauenklinik, Technischen Universität, München, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Schmitt
authors.forename: O
authors.initials: O
authors.lastname: Wilhelm
authors.forename: F
authors.initials: F
authors.lastname: Jänicke
authors.forename: V
authors.initials: V
authors.lastname: Magdolen
authors.forename: U
authors.initials: U
authors.lastname: Reuning
authors.forename: H
authors.initials: H
authors.lastname: Ohi
authors.forename: N
authors.initials: N
authors.lastname: Moniwa
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
authors.forename: U
authors.initials: U
authors.lastname: Weidle
authors.forename: H
authors.initials: H
authors.lastname: Graeff
mesh_terms: D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000628:therapy*; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis / Q000378:metabolism; D010960:Plasminogen Activators / Q000378:metabolism; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000378:metabolism; D055293:Receptors, Urokinase Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis / Q000378:metabolism
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator